Novel Therapies for Treating Familial Hypercholesterolemia

  title={Novel Therapies for Treating Familial Hypercholesterolemia},
  author={Salman Jamaluddin Bandeali and Jad Daye and Salim S. Virani},
  journal={Current Atherosclerosis Reports},
Familial hypercholesterolemia is an inherited disorder associated with early accelerated atherosclerosis with morbidity and mortality resulting from premature cardiovascular disease. Affected individuals have extreme elevations in low-density lipoprotein cholesterol levels. Patients usually do not achieve target reductions in cholesterol levels with conventional antihyperlipidemic pharmacotherapy. This unmet need has resulted in the recent development and approval of novel therapies targeting… Expand
Role of Lipoprotein Apheresis in Cardiovascular Disease Risk Reduction
It was concluded that LA is a safe and effective technique that could be considered in the management of hypercholesterolemia and future risk and Randomized control trials would further support a role for LA as a therapeutic option. Expand
Novel emerging therapies in atherosclerosis targeting lipid metabolism
New options now exist for the prevention of atherosclerosis in patients that are not optimized on statin therapy and newly approved non-statin-based therapies such as ezetimibe, icosapent ethyl (IPE), and bempedoic acid are discussed. Expand
Intracellular cholesterol accumulation and coenzyme Q10 deficiency in Familial Hypercholesterolemia.
Familial Hypercholesterolemia pathophysiology in skin fibroblasts derived from FH patients harboring heterozygous mutations in the LDL-receptor was examined, suggesting dysregulation of the mevalonate pathway. Expand
Current and future trends in the lipid lowering therapy.
A review of recent clinical findings and continuous research in the field of hypolipidemic drugs seems practical to review recent data and show potential new pathways that may be useful in the treatment of hyperlipidemia. Expand
Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session
The review highlights selected studies related to cardiovascular disease (CVD) prevention that were presented at the American College of Cardiology 2020 Virtual Scientific Session (ACC.20/WCC) and discusses the use of polygenic risk score with low density lipoprotein cholesterol (LDL-C) and systolic blood pressure (SBP) on lifetime cardiovascular risk. Expand
Innovative Target Therapies Are Able to Block the Inflammation Associated with Dysfunction of the Cholesterol Biosynthesis Pathway
In this review, inhibitors of cholesterol synthesis, mitochondria-targeted drugs and inhibitors of the inflammasome are focused on. Expand


Familial Hypercholesterolemia and the Atherosclerotic Disease
It is difficult to achieve an ideal level of LDL-C with a single statin therapy in the majority of FH patients, and lipid lowering combination therapy with the recently-introduced ezetimibe has shown more encouraging results. Expand
Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder.
Mipomersen sodium was evaluated in a randomized, clinical pivotal trial, in which a 200-mg dose was administered weekly for 6 months in 34 individuals with HoFH and in 17 placebo controls, and showed considerable individual variability. Expand
Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
Recommendations for the screening and treatment of patients with Familial Hypercholesterolemia include mipomersen, which was approved by the FDA in January 2013 and received FDA approval for use only in patients with HoFH, and novel treatments currently in development include PCSK9 inhibitors. Expand
Novel therapies and new targets of treatment for familial hypercholesterolemia.
A number of novel pharmaceutical approaches to LDL cholesterol-lowering have been in development and hold significant potential for improving treatment options for patients with familial hypercholesterolemia. Expand
Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment.
Treatment typically involves lipid-modifying medical therapy as well as mechanical removal of plasma LDL by means of apheresis and further therapeutic advancements currently under investigation promise hope of further improvements in survival and improved quality of life. Expand
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
This report goes beyond previously published guidelines by providing specific clinical guidance for the primary care clinician and lipid specialist with the goal of improving care of patients with FH and reducing their elevated risk for CHD. Expand
Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.
Only a small proportion of patients with heFH reaches the LDL-c treatment target of <2.5mmol/l, and the results emphasize the need for better monitoring, better utilization of available medication and for new treatment options in heFH to further decrease LDL- c levels. Expand
Molecular genetics of the LDL receptor gene in familial hypercholesterolemia
79 additional mutations are described and the insights that all 150 mutations have provided into the structure/function relationship of the receptor protein and the clinical manifestations of FH are reviewed. Expand
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment.
A subset of patients with very high plasma LDL-C levels have monogenic forms of hyper-cholesterolemia, which are associated with the deposition of cholesterol in tissues, producing xanthomas and coronary atherosclerosis, and how insights gleaned from the study of these disorders may be extended to the treatment of hypercholesterine in the general population is discussed. Expand
Novel nonstatin strategies to lower low-density lipoprotein cholesterol
There remains an unmet need to reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients who are maximized on current therapy or intolerant to statins. Several novel agents have beenExpand